110 EAST 59TH STREET, NEW YORK, NY
2026 Annual General Meeting of Shareholders - Royalty Pharma plc Votes
Earnings Release
Positive Phase 3 Results for Daraxonrasib in Metastatic PDAC Announced
Annual Report to Security Holders
Reports Q4 and Full Year 2025 Results
Executive Transition - George W. Lloyd to Step Down as Chief Legal Officer
FDA Approves MYQORZO for Treatment of Obstructive Hypertrophic Cardiomyopathy
Reports Third Quarter 2025 Results
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
Automatic Shelf Registration Statement